Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say

Incyte (INCY) reported $1.37 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 20.1%. EPS of $2.26 for the same period compares to $1.07 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.26 billion, representing a surprise of +8.71%. The company delivered an EPS surprise of +36.14%, with the consensus EPS estimate being $1.66.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Incyte performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenues- Product revenues: $1.15 billion versus the eight-analyst average estimate of $1.09 billion. The reported number represents a year-over-year change of +19.4%.Revenues- Product royalty revenues: $171.12 million versus $164.43 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +9.1% change.Net product revenues- Iclusig: $37.58 million compared to the $30.63 million average estimate based on eight analysts. The reported number represents a change of +26.4% year over year.Net product revenues- Pemazyre: $22.74 million versus $21.99 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +10.1% change.Net product revenues- Minjuvi/ Monjuvi: $41.99 million versus the eight-analyst average estimate of $37.87 million. The reported number represents a year-over-year change of +33.6%.Net product revenues- Opzelura: $187.97 million versus the eight-analyst average estimate of $179.13 million. The reported number represents a year-over-year change of +35%.Net product revenues- Jakafi: $791.07 million versus the eight-analyst average estimate of $769.99 million. The reported number represents a year-over-year change of +6.7%.Net product revenues - Niktimvo: $45.83 million versus $42.68 million estimated by seven analysts on average.Net product revenues- Zynyz: $22.67 million versus the seven-analyst average estimate of $9.46 million. The reported number represents a year-over-year change of +3167.2%.Royalty revenues- Olumiant: $37.11 million versus the seven-analyst average estimate of $37.17 million. The reported number represents a year-over-year change of +6.7%.Royalty revenues- Tabrecta: $6.51 million versus the seven-analyst average estimate of $7.15 million. The reported number represents a year-over-year change of +9.9%.Royalty revenues- Jakavi: $125.65 million versus $119.18 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +8.6% change.View all Key Company Metrics for Incyte here>>>Shares of Incyte have returned +11% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Quantum Computing Stocks Set To SoarArtificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.Access the Report Free Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Incyte Corporation (INCY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks